On September 18, 2024, PPMD hosted an informative community webinar featuring representatives from ITF Therapeutics, PPMD, and the Little Hercules Foundation. The session focused on DUVYZAT (givinostat), a recently approved HDAC inhibitor for the treatment of Duchenne, and the support programs available for patients and families.

• ITF Therapeutics provided an overview of DUVYZAT, explaining its classification as an HDAC inhibitor and its mechanism of action in treating muscular dystrophy. The ITF ARC patient services program was introduced, outlining the resources and assistance available to help families navigate access and coverage for DUVYZAT.
• PPMD highlighted our comprehensive online access and coverage resources, including therapy-specific information and sample letters of medical necessity. We also shared information about PPMD For You, our personalized support program that can help families navigate benefits and access programs.
• The Little Hercules Foundation discussed their full suite of support services for families facing insurance challenges, including one-on-one case management, appeal letter drafting, and engagement with payers and elected officials.

Watch the Webinar Recording

We are grateful to all who joined us and contributed their insights and questions. PPMD remains committed to working to ensure that every family has the support they need to access the latest therapies, and we will continue to expand and update our resources as they are available. Together, we are working toward a future where every person with Duchenne and Becker has the resources and opportunities they deserve.